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Abstract
Pertussis is an acute infectious disease caused by the organism Bordetella pertussis and characterized by a "whooping
cough." Incidence of the disease had declined since the development of a vaccine, but is now increasing in reported cases.
This increase has been attributed to both an increased
awareness but also surmised to be related to a decrease in
vaccinations. The pertussis vaccine is given in conjunction
with tetanus and diphtheria vaccines to children before the
age of 6 in five separate injections over the course of four to
six years. A booster is now recommended for the older child
and adults due to the declining protection of the vaccine over
time. Pertussis is highly contagious and early treatment with
a macrolide antibiotic is recommended to limit the severity
and prevent transmission. It can be deadly in infants, which
is why prevention via immunizations is so important. The
pharmacist can assist with advising individuals of the importance of vaccination.
Introduction
Pertussis, also known as whooping cough, is an acute infectious disease caused by the organism Bordetella pertussis
that has a history of being a common preventable yet fatal
childhood disease. Since the development of the pertussis
vaccine in the 1940s, the incidence rate has decreased by at
least 75 percent among children. But recently, the number of
reported cases of pertussis has increased. The Centers for
Disease Control and Prevention (CDC) believes that this increase could be due to heightened awareness and improvement in clinicians' ability to diagnose pertussis, but they also
believe that a large portion of the disease goes unreported or
unrecognized.1 According to the Council on Foreign Relations, since 2008 there have been 65,457 reported pertussis
outbreaks around the world with an astonishing 56.4 percent
of those cases happening in the United States. 2 Due to rapid
spread of disease, these outbreaks usually occur in clusters.
Over the years, these clusters of outbreaks experience peaks
of incidence every three to five years and continue to follow
this same pattern.3 With the use of patient education on signs
and treatment of pertussis as well as prevention and vaccination, this recent spike in incidence rate can be controlled.
Disease State
Bordetella pertussis is a gram-negative bacteria that produces many biologically active products, most notably the
pertussis toxin (PT). Pertussis toxin modifies inhibitory G
proteins rendering them unable to inhibit adenylyl cyclase,
an enzyme that plays an essential role in transmitting signals
to secondary messengers. Thus, PT forces other activated G
proteins into continuous signaling, leading to various unwanted consequences such as immune suppression, which
would promote bacterial colonization and potentially in-

crease transmission of the disease.4 Physiologically, Bordetella pertussis attaches to the cilia of respiratory epithelial
cells and paralyzes them. This causes pulmonary secretions
to be inadequately cleared and leads to inflammation in the
respiratory tract.1
This very contagious disease is spread from person to person, most commonly by inhalation of droplets from a cough
or a sneeze. 5 Symptoms usually start to occur within seven to
10 days of initial transmission. These symptoms start off as
cold-like with a runny nose and mild cough along with a lowgrade fever. This can develop into a severe cough or apnea, a
pause in breathing pattern that is very common in infants.
This severe cough can become so violent and rapid that all
the air from the lungs is expelled and the patient is forced to
inhale, which results in the characteristic "whooping" sound.
These severe coughs can cause young children to vomit and
become extremely lethargic.6 Complications that occur in
infants and children include pneumonia, convulsions, severe
apnea, encephalopathy or even death. In teens and adults,
complications can include weight loss, loss of bladder control, passing out or even rib fractures from severe coughing.7
Infants develop the most severe complications of pertussis
because their immune systems are not fully developed at
birth and cannot offer full protection against the disease. Although receiving vaccines helps infants fight certain diseases,
they are still vulnerable to disease until their immune system
is fully developed. If left untreated, these complications can
lead to hospitalization of young children and infants in which
one to two out of 100 infants will die due to pertussis.7 Diagnosis of pertussis involves evaluation of symptoms, a physical exam and a laboratory test of respiratory secretions.
These secretions are taken from the back of the throat
through the nose and are further evaluated for the presence
of Bordetella pertussis.a

Prevention
The recommended form of prevention for pertussis is
through immunizations. 9 Two vaccines providing pertussis
protection are available; Pediatric Diphtheria, Tetanus, and
acellular Pertussis vaccine (DTaP) and Adult Tetanus, diphtheria, and acellular pertussis vaccine (Tdap). The use of the
upper-case letters in the abbreviations designate the doses of
tetanus (T) and diphtheria (D) toxoids, and pertussis (P) vaccine are full-strength. Reduced doses of diphtheria and pertussis are represented by the lower-case "d" and "p" in the
adult vaccination. The lowercase "a" in both vaccines represents "acellular" which means only part of the pertussis organism is present.1° The DTaP is administered to children 6
years and younger in five separate doses usually occurring at
ages 2 months, 4 months, 6 months, 15 to 18 months and 4 to
6 years. The Tdap is recommended for children ages 7 to 18
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either the DTaP or Tdap vaccines before, adults ages 19 and
older should receive a dose of Tdap as soon as possible to
protect themselves.11
Along with first time protection, Tdap is also employed as a
booster available for older children and adults ages 11 to 64
years, and is especially recommended for patients when
coming into contact with infants. Adults may receive Tdap
instead of their next scheduled tetanus booster shot, which
are usually administered every 10 years. This dose of Tdap
can be given before the next 10-year mark.11 Recent studies
have shown that the immunity generated by these vaccines,
especially DTaP, decreases over time. This waning immunity
has led to numerous outbreaks affecting previously immunized individuals. One report studied a population of children between ages 4 and 12 and placed them into groups
based on if they possessed pertussis. It was found that every
year after receiving their fifth dose of the DTaP vaccine, the
children had a 42 percent increased probability in obtaining
pertussis. 12 This means the DTaP vaccine would only be
71 percent effective five years after administration when it
was 95 percent effective initially. 13 The results of this study
highlight the need for children to receive boosters of the
Tdap vaccine in order to stop this waning immunity.
Special considerations about receiving the Tdap vaccine are
made for pregnant women, health care professionals and the
elderly. During each pregnancy, a woman should receive a
dose ofTdap at 27 to 36 weeks to transfer pertussis antibodies to her baby and to protect herself. These antibodies provide the newborn with protection until they begin receiving
DTaP vaccines after birth. If the mother has not received
Tdap, it is recommended she receive the vaccine in the postpartum period, up to six weeks after birth. Adults 65 years or
older should receive a single dose of the Tdap vaccine. 11
Health care personnel, such as pharmacists, who work in
close contact with patients and have not previously been administered the Tdap vaccine should receive it to prevent
spreading pertussis to their patients.
Of course, if a child or adult is moderately or severely ill or
allergic to any ingredients, they should not receive either
vaccine. 14 In general, the ingredients of purified DTaP /Tdap
vaccines administered in the United States contain reduced
pertussis toxin, trace amounts of mercury and an aluminum
adjuvant. 15 The mechanism of action of these vaccines to prevent pertussis is not fully known, but an immune response is
stimulated and protective antibodies are formed. Along with
vaccines, prevention using post-exposure prophylaxis in atrisk individuals who have come in contact with a contaminated person can be avoided with the use of prophylactic
antibiotics including azithromycin, clarithromycin and erythromycin.16 These antibiotics are known as macrolides which
have bacteriostatic activities.17
As the most accessible health care professionals, pharmacists
are able to play a large role in the prevention of pertussis. In
most states, pharmacists are able to administer the Tdap vac-

cine to patients ages 10 and older who have a prescription.ls
This places pharmacists at the center of pertussis prevention.
Since retail pharmacists are in constant contact with patients, it proposes the chance to ask high-risk populations,
pregnant women and elderly, if they have received their
Tdap vaccines. Plus, by examining prescriptions and communicating with patients, pharmacists can recognize if someone
is being treated for pertussis. This provides the pharmacist
with an opportunity to counsel the patient about the danger
of pertussis to infants and ways to minimize the spread of
pertussis like good hand washing. Overall, pharmacists possess the ability to educate their communities about pertussis
prevention while also administering the Tdap vaccine.

Acute Treatment
Even though multiple prevention techniques against pertussis exist, in 2012, the United States experienced 48,277 cases
of pertussis reported to the CDC. 1 9 Although prophylactic
antibiotics are used to prevent the development of pertussis
in at-risk individuals, these antibiotics are mainly used to
treat those already afflicted by the illness. Antibiotics including azithromycin, clarithromycin and erythromycin are commonly employed treatment medications. Because erythromycin and clarithromycin have a higher propensity to cause
gastrointestinal irritation, azithromycin is the preferred antibiotic to be used in pertussis treatment. When used in patients 6 months and older, a 10 mg/kg single dose is given on
day 1 and then a 5 mg/kg single dose is administered days 2
through 5. The second-line option is clarithromycin given as
two divided doses of 15 mg/kg/day to patients over 1 month
old for seven days. A doctor can also prescribe erythromycin
for pertussis treatment which is typically given as four
divided daily doses of 40 to 50 mg/kg/day administered for
14 days to patients over 1 month old. At least five days of
treatment are required before the patient should leave isolation, and it is important for the patient to complete the drug
schedule fully.zo Since this disease is highly contagious, those
with pertussis should stay isolated and avoid contact with
other people, especially the unimmunized and infants. Early
treatment is necessary to stop pertussis from spreading, and
if the medications are administered before coughing fits begin, the severity can be decreased. These medications only
reduce the person's infectivity and do not alter the disease's
clinical course. Once the individual has been infected with
pertussis for three weeks, the medications are not useful because the bacteria is now absent from the body.s
Along with antibiotics, simple adjustments can aid the treatment of pertussis and stop its spread. Those individuals suffering from pertussis should drink plenty of fluids to avoid
dehydration. Plus, minimizing irritants such as smoke and
dust along with using a cool mist vaporizer helps alleviate an
ill person's cough. A key way to stop the spread of pertussis
is as simple as good hand washing. Overall, the treatment
options for pertussis stop the spread and decrease the severity of pertussis. More serious cases of pertussis may require
hospitalization, especially in infants.3 Since pharmacists are
very accessible, counseling patients on these treatment
points is convenient and beneficial to the community.
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Special Populations
There are many special populations who are strongly advised to get the pertussis vaccine. The first population is
infants and children, in which the highest incidence rate of
pertussis occurs. Along with the vaccine, parents should be
advised to keep their children away from anyone with cold
symptoms or anyone coughing. The second population is
caregivers of infants, who should get the vaccine and practice
good hygiene in order to prevent them from spreading pertussis to children. Caregivers can collectively include parents,
babysitters and other adults who have close contact frequently with young children. Another population that is recommended to get the vaccine is pregnant women or anyone
around a pregnant woman or newborn. This is also a prevention measure taken to protect the child from contracting pertussis soon after birth. A more general population is anyone
above preteen age who has not had a booster vaccine. This is
solely for prevention of any future pertussis infection and to
ensure that the individual has the maximum protection available. This is especially stressed in the elderly population in
which immune systems are not as strong. Finally, international travelers should be especially cautious about hygiene
and being up to date on the vaccine. Traveling to other countries that have outbreaks of pertussis can put a traveler at
great risk to contract that disease, and it also heightens the
risk that the traveler will bring the disease back to their
country and cause an outbreak there.9

Disease Epidemiology
Even with vaccinations available to protect a majority of the
population, pertussis is still considered as endemic within
the United States.3 Since 2003, pertussis has been on the rise
in the Midwest and California.21 Reported cases of pertussis
across the country jumped to 48,277 cases in 2012, from
18,719 cases in 2011. A general increase in reporting is to
blame for a portion of the jump, but the doubling in reported
cases is troubling given that pertussis is easily preventable.
While most cases of pertussis can be treated with little to no
lasting sequelae, cases in infants can be especially severe,
with high mortality rates.22 The importance of herd immunity has emerged over the years while the number of reported pertussis cases continues to climb.
In 2010, the United States saw its largest pertussis outbreak
since 194 7, in a Californian community. With 9,120 reported
cases and 10 deaths, this outbreak was one of the first to be
studied in relation to vaccination rates. Atwell et al. studied
the rate of pertussis spread among clusters of nonmedical
exemptions (NME) in kindergartners. Californian parents
obtained NMEs if vaccines were seen to be against their religious or philosophical beliefs. Using the Californian Department of Health's reported pertussis data and Kulldorff spatial
scans, Atwell et al. found statistically significant higher rates
of pertussis among communities with higher rates of NMEs.
This study provides health care professionals with a strong
correlation between vaccinations and pertussis prevention.2 1
In describing the importance of vaccinations to the prevention of pertussis to patients, a term commonly used is "herd
immunity." Herd or community immunity is defined by the
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National Institute of Allergy and Infectious Disease as immunizing a critical portion of the population against a disease,
thereby preventing an outbreak and protecting a smaller
portion of the population which may not be able to receive
vaccinations due to health or other rationale.23 Childhood
diseases such as polio and measles are essentially unheard of
in first world countries due to the high vaccination rates
among the children able to receive vaccinations. This high
vaccination rate and immunity protects patients who may
not be able to receive vaccinations due to disease states that
may leave them immunocompromised or resistant to vaccination. As the number of people opting out of vaccinations
grows, the herd immunity of communities within the United
States weakens. This is especially troubling due to the disease's severe threat to infants. By informing patients of this
concept while promoting vaccinations, high-risk populations
can be easily protected until they are able to receive the vaccination themselves.

Conclusion
Pharmacists are one of the most readily available health care
professionals and can therefore play an important role in
counseling patients on the pertussis vaccination. When counseling patients about important vaccinations, pharmacists
may run into patients hesitant to vaccinate due to many different reasons. The most common reasons include a belief
that the vaccine-prevented disease no longer poses any risk,
a doubt in the safety of the vaccine or a belief that the vaccine
may overload a child's immune system or be linked to autism
(which has been proven to be incorrect in multiple peerreviewed studies). Conservative forms of Islam, Judaism and
Christianity have reasons against vaccinations, often because
of the production or contents of the vaccine. When counseling parents who are vaccine-hesitant, Dr. John Harrington
outlines eight points that health care professionals should
keep in mind. First, health care professionals should begin
having vaccination conversations early (such as an infant's
first pediatrician visit), and pharmacists can distribute vaccine information sheets often to promote questions and conversations. While counseling, it is important to take the time
to listen to all questions without patronizing the patient.
Health care professionals should never offend the patient or
become offended by earnest questions. Acknowledging
possible peer-reviewed risks, using clear, patient-friendly
language, and respecting a patient's authority in decisionmaking allows for open conversations with patients about
vaccinations. Pharmacists can also explain the reduction of
pain for children receiving vaccinations through the use of
sucrose or swaddling. 24 Community pharmacists can play a
role in many of these steps by being available for patients
with questions. Taking extra time to explain vaccinations or
distribute educational material to the patient who has
become a new parent, will add on to the information many
parents will be receiving from their child's pediatrician. By
educating vaccine-hesitant patient populations, pharmacists
can help increase pertussis vaccination rates and help
reverse the outbreak trend.
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